Posted by Michael Wonder on 30 Sep 2017
Institute for Clinical and Economic Review's final report confirms inadequate evidence to compare outcomes of PARP inhibitors for ovarian cancer, highlights poor cost-effectiveness, particularly for maintenance therapy
29 September 2017 - The ICER has issued a final evidence report assessing the comparative clinical effectiveness and value of poly ADP-ribose polymerase (PARP) inhibitors for treatment of ovarian cancer.
The report includes a summary of a public meeting of the Midwest Comparative Effectiveness Public Advisory Council(Midwest CEPAC), during which the independent Council deliberated and voted on evidence presented in ICER’s report.
“Our report and meeting highlighted the need for further research on the long-term efficacy and safety of PARP inhibitors. In particular, information on improvement in overall survival is not yet available, and the trials of each agent differ in study population, design, and measurement of key outcomes. Some key studies involved no comparison to alternative treatments. Further, the high costs of the drugs do not align with their benefit to patients,” said Dan Ollendorf, PhD, ICER’s Chief Scientific Officer.
